• Clinical Trials - Lymphoma

    Study Objective Contact
    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Of RAD001 Adjuvant Therapy In Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab Chemotherapy [LCID Study Number: 2010-002] This study is being done to see if giving RAD001 can reduce the chance of relapse when it is given to patients with diffuse large B-cell lymphoma that is in complete remission. Rad001 is currently not approved by the FDA for use in this situation therefore, this treatment is considered experimental. Principal Investigator(s):
    Tarun Kewalramani, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon,
    Nancy M. Campbell, RN.
    An Open-Label, Randomized, Phase 2 Study to Assess The Effectiveness Of RCHOP With Or Without VELCADE In Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma [LCID Study Number: 2010-062] There are two main categories of DLBCL- 1) germinal center (GC) type and 2) non-GC type. The standard treatment for both types of DLBCL is a combination of drugs called RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Unfortunately, RCHOP works less well in patients with non-GC DLBCL. However, a better treatment than RCHOP for patients with non-GC DLBCL is not currently known. Principal Investigator(s):
    Tarun Kewalramani, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon,
    Nancy M. Campbell, RN.
    S0806, A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) [LCID Study Number: 2012-004] The standard treatment for DLBCL is a combination of the drugs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (called "RCHOP"). In many patients with DLBCL the lymphoma can return (“relapse”) after treatment with RCHOP. Vorinostat is a drug that may be effective in treating DLBCL. This experimental study is being done to see how well the combination of vorinostat and RCHOP can work to reduce the chance of DLBCL returning. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Tarun Kewalramani, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Donna Cossar.